Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | RAB9A | P51151 | 7/20 | 0.36 |
| ▸ | NPC1 | O15118 | 6/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.35 |
| ▸ | GRM5 | P41594 | 4/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | GBA1 | P04062 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1191872 | 0.78 | SORT1 (0.44) | KMT2ARAB9ANPC1ALDH1A1MAPK1 | |
| SCHEMBL25286918 | 0.78 | KEAP1 (0.42) | KMT2AMEN1RAB9ANPC1SORT1 | |
| SCHEMBL13506291 | 0.78 | GRM5 (0.40) | KMT2AMEN1RAB9ANPC1ALDH1A1 | |
| SCHEMBL21555674 | 0.78 | RAB9A (0.42) | KMT2AMEN1RAB9ANPC1ALDH1A1 | |
| SCHEMBL31742472 | 0.77 | PTGER2 (0.39) | — | |
| SCHEMBL15091115 | 0.77 | CYP17A1 (0.39) | KMT2AMEN1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL29971093 | 0.77 | CYP17A1 (0.39) | KMT2AMEN1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL15679602 | 0.76 | RAB9A (0.42) | RAB9ANPC1ALDH1A1MAPK1SMN1; SMN2 | |
| SCHEMBL20265391 | 0.75 | KMT2A (0.38) | KMT2AMEN1RAB9ANPC1ALDH1A1 | |
| SCHEMBL27199725 | 0.75 | ADORA2B (0.40) | KMT2AMEN1RAB9ANPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240050430-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2024-02-15 | — | — | US | disclosed |
| US-11814391-B2 | Macrocyclic compounds for the treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| EP-3897832-B1 | N-(PYRIDIN-2-YLSULFONYL)CYCLOPROPANECARBOXAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF A CFTR MEDIATED DISEASE | NOVARTIS AG (CH) | 2023-10-11 | — | — | EP | disclosed |
| EP-3788038-B1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC (US) | 2023-10-11 | — | — | EP | disclosed |
| US-11766436-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-20220395504-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2022-12-15 | — | — | US | disclosed |
| US-20220033407-A1 | N-(pyridin-2-ylsulfonyl)cyclopropanecarboxamide Derivatives and their Use in the Treatment of Disease | NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC. | 2022-02-03 | — | — | US | disclosed |
| EP-3897832-A1 | N-(PYRIDIN-2-YLSULFONYL)CYCLOPROPANECARBOXAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF A CFTR MEDIATED DISEASE | Novartis AG (CH) | 2021-10-27 | — | — | EP | disclosed |
| US-11090304-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2021-08-17 | — | — | US | disclosed |
| EP-3846803-A2 | MACROCYCLIC COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS | Achillion Pharmaceuticals, Inc. (US) | 2021-07-14 | — | — | EP | disclosed |
| US-10954214-B2 | Pyrazole derivatives as MALT1 inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2021-03-23 | — | — | US | disclosed |
| WO-2020128768-A1 | N-(PYRIDIN-2-YLSULFONYL)CYCLOPROPANECARBOXAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF A CFTR MEDIATED DISEASE | NOVARTIS AG (CH) | 2020-06-25 | — | — | WO | disclosed |
| US-20190343838-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2019-11-14 | — | — | US | disclosed |
| EP-3558969-A1 | PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS | Janssen Pharmaceutica NV (BE) | 2019-10-30 | — | — | EP | disclosed |
| WO-2018119036-A1 | PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS | JANSSEN BIOTECH, INC. (US) | 2018-06-28 | — | — | WO | disclosed |
| US-20180170909-A1 | PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS | JANSSEN-CILAG (FR) | 2018-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190343838-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | KMT2A 2069/4885MEN1 296/4885RAB9A 70/4885 |
| US-11090304-B2 | KRAS G12C inhibitors and methods of using the same | KRAS, NRAS, HRAS | KMT2A 2069/4885MEN1 296/4885RAB9A 70/4885 |
| US-10954214-B2 | Pyrazole derivatives as MALT1 inhibitors | MALT1, PPP3R1, SQSTM1 | KMT2A 3369/4885MEN1 769/4885RAB9A 979/4885 |
| US-20220033407-A1 | N-(pyridin-2-ylsulfonyl)cyclopropanecarboxamide Derivatives and their Use in the Treatment of Disease | CFTR, PKD2, PKD1 | KMT2A 3137/4885MEN1 3520/4885RAB9A 2886/4885 |
| US-20220395504-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | KMT2A 2069/4885MEN1 296/4885RAB9A 70/4885 |
| US-20240050430-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | KMT2A 2069/4885MEN1 296/4885RAB9A 70/4885 |
| US-11766436-B2 | KRAS G12C inhibitors and methods of using the same | KRAS, NRAS, HRAS | KMT2A 2069/4885MEN1 296/4885RAB9A 70/4885 |
| US-20180170909-A1 | PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS | MALT1, PPP3R1, SQSTM1 | KMT2A 3369/4885MEN1 769/4885RAB9A 979/4885 |
| US-11814391-B2 | Macrocyclic compounds for the treatment of medical disorders | CFD, TFPI, CFH | KMT2A 4672/4885MEN1 108/4885RAB9A 2855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.